A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Icotrokinra (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ANTHEM-UC
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 10 Mar 2025 Results published in the Johnson & Johnson media release.
- 10 Mar 2025 Primary endpoint has been met. (Percentage of Participants with Clinical Response at Week 12), according to Johnson & Johnson media release.
- 07 Nov 2024 According to a Protagonist Therapeutics media release, top line results for the Phase 2b ANTHEM is expected in Q1 2025.